David Risinger Analyst PerformanceSenior Managing Director & Senior Research Analyst at Leerink PartnersDavid Risinger is a stock analyst at Leerink Partners focused in the healthcare sector, covering 36 publicly traded companies. Over the past year, David Risinger has issued 41 stock ratings, including buy and hold recommendations. While full access to David Risinger's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Risinger's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings176 Last 11 YearsBuy Recommendations48.82% 83 Buy RatingsCompanies Covered36 Unique Companies Ratings Distribution170RatingsDistribution of strong buy, buy, hold, and sell ratings by David Risinger.RatingPercentageCount Strong Buy2.4%4 ratings Buy46.5%79 ratings Hold47.1%80 ratings Sell4.1%7 ratingsOut of 170 total stock ratings issued by David Risinger at Leerink Partners, the majority (47.1%) have been Hold recommendations, followed by 46.5% Buy, 4.1% Sell, and 2.4% Strong Buy.Best & Worst CallsBest Call0000.0%CNTAMar 2023Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BHCJul 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ66.7% of companies on NASDAQ24 companiesNYSE33.3% of companies on NYSE12 companiesDavid Risinger, an analyst at Leerink Partners, currently covers 36 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare34 companies94.4%Miscellaneous2 companies5.6%David Risinger of Leerink Partners specializes in stock coverage within the Healthcare sector, with additional focus on companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY18 companies50.0%PHARMACEUTICALS15 companies41.7%Miscellaneous2 companies5.6%HEALTHCARE PROVIDERS & SERVICES1 company2.8% About David RisingerDavid Risinger, CFA is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Diversified Biopharmaceuticals. Prior to joining the Firm in 2022, David’s most recent Wall Street role was Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to Morgan Stanley, he was head of Global Healthcare Research and Senior US Pharmaceutical analyst at Merrill Lynch & Co. He started his Wall Street career at Dillon, Read & Co. He has been a top-ranked analyst by Institutional Investor for decades, including achieving Runner-Up rankings in both Major Pharmaceuticals and Specialty Pharmaceuticals in 2021. He earned his Bachelor of Arts in Political Science from Bucknell University and holds the Chartered Financial Analyst designation.Follow on LinkedIn David Risinger's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsHALOHalozyme Therapeutics11/6/2026Downgrade$103.63$117.00Hold$0.0000.00% ROIAMGNAmgen11/5/2026Boost Price Target$460.28$464.00Market Perform$0.0000.00% ROIABBVAbbVie11/2/2026Boost Price Target$289.67$342.00Outperform$0.0000.00% ROIREGNRegeneron Pharmaceuticals11/2/2026Boost Price Target$964.13$997.00Market Perform$0.0000.00% ROILLYEli Lilly and Company10/21/2026Boost Price Target$1,265.96$1,316.00Outperform$0.0000.00% ROITRAXFirst Tracks Biotherapeutics10/16/2026Boost Price Target$36.04$90.00Outperform$0.0000.00% ROIJNJJohnson & Johnson10/14/2026Lower Price Target$251.39$272.00Outperform$0.0000.00% ROIBMYBristol Myers Squibb10/5/2026Downgrade$61.16$59.00Market Perform$0.0000.00% ROIANABAnaptysBio9/23/2026Lower Price Target$53.92$81.00Outperform$0.0000.00% ROIENTXEntera Bio9/18/2026Initiated Coverage$3.03$9.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. LTGOLatigo Biotherapeutics9/1/2026Initiated Coverage$22.02$36.00Outperform$0.0000.00% ROILTGOLatigo Biotherapeutics9/1/2026Initiated Coverage$22.26$36.00Outperform$0.0000.00% ROISCTXScribe Therapeutics8/18/2026Initiated Coverage$21.19$37.00Outperform$0.0000.00% ROIREGNRegeneron Pharmaceuticals8/17/2026Boost Price Target$803.48$824.00Market Perform$0.0000.00% ROILGNDLigand Pharmaceuticals8/14/2026Initiated Coverage$288.22$330.00Outperform$0.0000.00% ROIHALOHalozyme Therapeutics8/7/2026Upgrade$85.76$110.00Outperform$0.0000.00% ROIBMYBristol Myers Squibb7/31/2026Boost Price Target$59.18$73.00Outperform$0.0000.00% ROILLYEli Lilly and Company6/25/2026Boost Price Target$1,115.98$1,232.00Outperform$0.0000.00% ROILLYEli Lilly and Company5/26/2026Set Price Target$1,066.59$1,119.00$0.0000.00% ROIROIVRoivant Sciences5/21/2026Set Price Target$32.41$42.00$0.0000.00% ROIANABAnaptysBio5/15/2026Set Price Target$62.77$90.00$0.0000.00% ROIJNJJohnson & Johnson5/13/2026Upgrade$224.44$265.00Outperform$0.0000.00% ROIKLRAKailera Therapeutics5/12/2026Initiated Coverage$22.93$36.00Outperform$0.0000.00% ROIORKAOruka Therapeutics4/30/2026Set Price Target$68.10$120.00$0.0000.00% ROIREGNRegeneron Pharmaceuticals4/30/2026Lower Price Target$746.54$792.00$0.0000.00% ROIANABAnaptysBio4/28/2026Boost Price Target$66.59$85.00Outperform$0.0000.00% ROITRAXFirst Tracks Biotherapeutics4/24/2026Initiated Coverage$19.00$46.00Outperform$0.0000.00% ROICNTACentessa Pharmaceuticals4/1/2026Downgrade$39.86$40.00Hold$0.0000.00% ROIORKAOruka Therapeutics3/16/2026Boost Price Target$41.52$86.00Outperform$0.0000.00% ROIAMGNAmgen3/5/2026Reiterated Rating$367.60$355.00Market Perform$0.0000.00% ROIXOMAXOMA Royalty2/24/2026Reiterated Rating$26.79Outperform$0.0000.00% ROIXOMAXOMA Royalty2/24/2026Boost Price Target$25.32$50.00Outperform$0.0000.00% ROILLYEli Lilly and Company2/5/2026Boost Price Target$1,057.10$1,296.00Outperform$0.0000.00% ROIAMGNAmgen2/4/2026Boost Price Target$338.59$355.00Outperform$0.0000.00% ROIBMYBristol Myers Squibb1/13/2026Boost Price Target$56.40$60.00Outperform$0.0000.00% ROILLYEli Lilly and Company1/5/2026Set Price Target$1,079.83$1,234.00$0.0000.00% ROIVRTXVertex Pharmaceuticals12/29/2025Boost Price Target$462.90$525.00Outperform$0.0000.00% ROILLYEli Lilly and Company12/18/2025Reiterated Rating$1,062.10Outperform$0.0000.00% ROIROIVRoivant Sciences12/15/2025Boost Price Target$22.10$32.00Outperform$0.0000.00% ROIXOMAXOMA Royalty12/11/2025Lower Price Target$26.76$45.00Outperform$0.0000.00% ROIYour free book is about to disappear (Ad)Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.Download the Safe Trade Options Formula book for free before access closesPCVXVaxcyte11/19/2025Set Price Target$49.53$77.00Outperform$0.0000.00% ROIROIVRoivant Sciences11/11/2025Reiterated Rating$21.17$29.00Outperform$00.0000.00% ROILLYEli Lilly and Company11/10/2025Upgrade$923.35$1,104.00Outperform$0000.0000.00% ROIIMAImageneBio10/24/2025Initiated Coverage$7.39$30.00Outperform$0.0000.00% ROIHALOHalozyme Therapeutics10/14/2025Upgrade$67.72$70.00Market Perform$000.0000.00% ROIVRTXVertex Pharmaceuticals9/25/2025Upgrade$376.62$456.00Outperform$000.0000.00% ROIROIVRoivant Sciences9/18/2025Boost Price Target$15.28$22.00Outperform$00.0000.00% ROIJNJJohnson & Johnson5/13/2025Downgrade$153.88$153.00Market Perform$000.0000.00% ROIVRTXVertex Pharmaceuticals5/6/2025Reiterated Rating$500.19$503.00Market Perform$000.0000.00% ROIVRTXVertex Pharmaceuticals5/6/2025Downgrade$450.03$503.00Hold$000.0000.00% ROIREGNRegeneron Pharmaceuticals2/5/2025Upgrade$697.05$834.00Outperform$000.0000.00% ROIJNJJohnson & Johnson1/23/2025Lower Price Target$146.81$169.00Outperform$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche BankBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.